Understanding the Barriers to Pediatric Oncologist Engagement and Accrual to Clinical Trials in National Cancer Institute–Designated Community Oncology Research Programs

David S. Dickens, MD1; Michael E. Roth, MD2; Brad H. Pollock, MPH, PhD3; and Anne-Marie Langevin, MD4

QUESTION ASKED: What do pediatric oncologists and research associates at National Cancer Institute Community Oncology Research Programs (NCORPs) experience regarding clinical trial enrollment barriers, educational needs, and understanding/navigating organizational structure?

SUMMARY ANSWER: The majority of participants reported a limited understanding of their NCORP structure and processes, a need for more education, as well as inadequate time and resources to manage their desired clinical research portfolio.

WHAT WE DID: We conducted two quality improvement surveys of pediatric clinical research staff at NCORP sites. The first was a web-based inquiry sent via e-mail to NCORP Children’s Oncology Group (COG) principal investigators (PIs) and lead clinical research associates (CRAs) containing questions designed to assess their general understanding of NCORP organization and structure as well as their educational and service needs. The second was a one-on-one telephone interview of COG PIs to identify specific barriers to physician engagement and patient enrollment in clinical trial research.

WHAT WE FOUND: The majority of NCORP COG PIs and CRAs (63%) expressed a lack in understanding of the NCORP, and approximately half expressed the need to receive education on strategies to work with medical oncologists, increase adolescent and young adult (AYA) clinical trial accrual, and increase cancer control study enrollment. The majority of COG PIs (78%) experienced at least one shared barrier to clinical trial enrollment. The most frequently cited barriers were inadequate protected time and research support (39% each).

BIAS, CONFOUNDING FACTORS: Our findings could be influenced by the biases inherent to surveys, including participant and interviewer bias. The surveys were primarily designed to help the COG NCORP Committee to improve its educational program and develop interventions to better serve the needs of its members and may not be generalizable beyond the domain of NCORP COG members.

REAL-LIFE IMPLICATIONS: Maximizing clinical trial enrollment is a key strategy to progress in the treatment of patients with cancer. Oncologists and lead CRAs serve critical roles in clinical trial design and implementation. These key individuals report inadequate education, time, and resources as potential barriers to full engagement in clinical research. Addressing these barriers has the potential to increase the rate of enrollment in clinical trials and therefore contribute to progress in cancer therapy for children and AYAs.

CORRESPONDING AUTHOR
David S. Dickens, MD, Department of Pediatrics, Division of Hematology, Oncology and Bone Marrow Transplantation, University of Iowa, Holden Comprehensive Cancer Center, 200 Hawkins Dr, BT1323, Iowa City, IA 52242; e-mail: david-dickens@uiowa.edu.
Understanding the Barriers to Pediatric Oncologist Engagement and Accrual to Clinical Trials in National Cancer Institute–Designated Community Oncology Research Programs

David S. Dickens, MD1; Michael E. Roth, MD2; Brad H. Pollock, MPH, PhD3; and Anne-Marie Langevin, MD4

PURPOSE Clinical trial participation leads to progress in cancer care. Principal investigators (PIs) and clinical research associates (CRAs) play key roles in the provision and maintenance of clinical trial portfolios at their sites. Previous studies have evaluated the educational and resource needs of adult oncology providers, but nothing to date has focused on providers of pediatric oncology care. We aimed to identify the educational needs and clinical trial participation barriers at National Cancer Institute Community Oncology Research Program (NCORP) Children's Oncology Group (COG) sites to improve the quality of site investigator engagement.

METHODS Quality improvement surveys of pediatric clinical research staff at NCORP sites were performed. The first was a web-based inquiry of NCORP COG PIs and lead CRAs to assess their general understanding of NCORP organizational structure and needs. The second survey of COG PIs was conducted by one-on-one telephone interviews aimed at identifying specific barriers to physician engagement and patient enrollment in clinical trial research.

RESULTS The majority of NCORP COG PIs and CRAs (63%) reported an incomplete understanding of NCORP structure, with approximately half expressing interest in developing stronger collaborations and engagement. Most NCORP COG PIs reported at least one shared barrier to clinical trial enrollment (78%), with inadequate protected time and research support (39% each) being the most frequently cited barriers.

CONCLUSIONS Contributions to pediatric cancer clinical research at COG NCORP sites could be enhanced through improved education, resources, and time allocation.

JCO Oncol Pract 16:e1060-e1066. © 2020 by American Society of Clinical Oncology

INTRODUCTION
Clinical trial enrollment benefits the individual patient by offering a chance for improved survival while also providing benefit to future patients by defining optimal treatments.1-6 Although the majority of surveyed US oncologists and patients with cancer view clinical trial enrollment as beneficial,7,8 most US patients with cancer do not participate in clinical trials. Efforts to explain this paradox have pointed to a variety of organizational, patient, and physician barriers to clinical trial enrollment.9 One organizational reality recognized decades ago was that the majority of US patients with cancer were not treated at academic institutions and simply did not have access to clinical trials.10 In response to this access disparity, the National Cancer Institute (NCI) funded a series of community-based oncology research programs throughout the United States to transport state-of-the-art cancer research into community settings that serve a large and diverse patient population.11 Initiated in 1983 as the Community Clinical Oncology Programs (CCOPs), adding the Minority-Based CCOPs in 1990 and being re-organized as the NCI Community Oncology Research Program (NCORP) in 2014, these programs aim to address oncology needs at community, minority/underserved, and rural minority/underserved sites. While NCORPs have shown substantial success with regard to providing clinical trial access to the greater US cancer population, the challenges of clinical trial enrollment have been similar to that seen in academia.12-14

One patient subgroup recently subject to much-needed scrutiny has been the adolescent and young adult (AYA) population, given the relative stagnation in
outcome improvement for many of the malignancies that afflict this age-group and the association of age with poor clinical trial participation.\textsuperscript{15} Within the AYA population, clinical trial availability and enrollment differ by organizational factors such as community versus academic sites and adult versus pediatric programs.\textsuperscript{3–5,16–18} Many NCORPs possess pediatric and adult components with shared infrastructure while offering academic institution–like clinical trial availability. It was previously hypothesized that NCORPs provide the ideal organizational design to optimize AYA enrollment. Unfortunately, when assessed for Children’s Oncology Group (COG) studies, there is evidence that CCOP-funded community sites enroll proportionally fewer AYA patients compared with non-CCOP sites.\textsuperscript{19} Emerging data suggest similar enrollment results when non-COG studies are considered.\textsuperscript{19a} Taken together, these results raised concerns about the level of engagement, integration, and recognition of pediatric and AYA components within their respective NCORPs.

The COG NCORP Committee (CNC) represents NCORP site interests within COG’s administrative and scientific activities. The CNC monitors and develops mechanisms to ensure robust treatment trial accrual from NCORP sites with an added focus on the development and conduct of studies in cancer prevention and control, cancer health disparities, and cancer care delivery research. The findings reported in this article were generated from quality improvement projects aimed at gathering phenomenological information from COG NCORP pediatric oncology clinical research staff on barriers to clinical trial engagement.

**METHODS**

**Study Design**

The CNC conducted two quality improvement surveys during the first NCORP grant cycle between December 2016 and January 2018. The first survey was conducted electronically through SurveyMonkey (SurveyMonkey, San Mateo, CA) between December 2016 and January 2017 and targeted the NCORP COG principal investigators (PIs) and lead clinical research associates (CRAs) at all 38 COG pediatric oncology programs. The second survey of NCORP COG site PIs was conducted through telephone interview led by D.S.D. and A.-M.L. between October 2017 and February 2018. All NCORP COG site PIs received e-mail notification from the interviewers. Nonresponders received a second e-mail notification. Responders then arranged for a time to conduct the telephone survey with the interviewer. Descriptive statistics are reported. These activities were reviewed by The University of Texas Health San Antonio institutional review board and deemed as quality improvement projects because they were designed to implement processes that will improve patient care at NCORP COG programs.

**Instrumentation**

Survey questions were codeveloped by CNC leadership and believed to be relevant to the understanding of the needs of clinical research investigators (Table 1). The first web-based survey consisted of 10 questions designed to assess a general understanding of NCORP structure and the CNC’s role in helping responders to achieve their accrual goals. The second 7-question telephone survey focused on barriers to clinical trial enrollment and collected PI experiences, observations, and ideas both in general and in specific domains. Responders were not required to answer every question and could make more than one comment for barrier assessment questions.

**RESULTS**

**Survey 1**

Of the 76 individuals surveyed, 44 responded, for a participation rate of 58%. The majority of NCORP COG PIs and CRAs (63%) did not understand or somewhat understood the NCORP in general. Portions were unfamiliar with key aspects of their NCORP, including the names of their NCORP PI (16%), the NCORP administrator (30%), and the NCORP itself (23%). Responders reported the need to receive education on strategies to work with medical oncologists (55%) and to increase accrual for cancer control studies (55%), AYA patients (48%), and therapeutic trials (38%). E-mails (80%), in-person sessions during the COG meeting (62%), and teleconferences/webinars (52%) were cited as the preferred modalities for receiving information. Other suggestions for program support were more timely information about the general functioning and funding of NCORPs, increasing access to multilanguage-translated consents, and increasing the number of active therapeutic and cancer control trials.

**Survey 2**

Overall, 23 of 38 NCORP COG PIs agreed to participate in a phone interview (61% response rate). The median number of years participants served as PI was 5 (30% held the PI position for ≤ 2 years), and they reported limited informational handoffs from previous institutional PIs. The mean reported clinical effort was 80%. With regard to NCORP board structure, budget, or grant writing, 8 (35%) of 23 NCORP COG PIs were not involved with any activity, 5 (22%) were engaged with all, and the rest had partial involvement. General barriers to enrollment were identified by 18 (78%) of the 23 responding NCORP COG PIs. The two most frequently cited barriers were insufficient research assistance and insufficient protected time to effectively manage patient recruitment efforts and the research portfolio (9 of 23; 39%). Other cited barriers were internally competitive studies, institutional research offices, consent fatigue for both investigators and patients, electronic health records, insurance coverage, and lack of patient and family knowledge about clinical trials. Prominent trends within the
### TABLE 1. NCORP COG Survey Questions

| Survey and Question No. | Question Text |
|-------------------------|---------------|
| Survey 1 (76 eligible recipients: NCORP COG PIs and CRAs) | |
| 1 | Do you know the name of your NCORP? (yes/no) |
| 2 | Do you know who your NCORP PI is? (yes/no) |
| 3 | Do you know who your NCORP administrator is? (yes/no) |
| 4 | Do you feel you understand the NCORP program? (yes/no/somewhat) |
| 5 | Is there anything about the NCORP program you would like more information on? (yes/no) |
| 6 | How would you prefer to receive the information? (check all that apply) |
| | E-mail |
| | Teleconference/webinar |
| | During the COG meetings |
| | At regional meetings |
| | Other |
| 7 | How can COG better serve our NCORP members? (free text) |
| 8 | How can COG support NCORP members in clinical trial accrual? (free text) |
| 9 | How can COG support NCORP members’ involvement in cancer control and cancer care delivery research? (free text) |
| 10 | Please identify topics you would like to discuss with other NCORP PIs. (check all that apply) |
| | AYA enrollments |
| | Strategies for increasing cancer control accrual |
| | Strategies for increasing treatment trial accrual |
| | Strategies for working with adult oncology colleagues |
| | NCORP administrative issues |
| | Other |

| Survey 2 (38 eligible recipients: NCORP COG PIs) |
|-------------------------|---------------|
| 1 | How long have you served as your institutional PI? |
| 2 | What percentage clinical full-time equivalency are you? |
| 3 | What administrative functions do you serve within your NCORP site? |
| | Board member |
| | Grant writing |
| | Budget management |
| 4 | Do you have any general barriers to enrollment in clinical trials? |
| 5 | What can be done to maximize enrollments in the following specific areas? |
| | Cancer care delivery research |
| | Cancer control |
| | AYA |
| | Minority and underserved populations |
| 6 | What is your preference for educational formats? |
| 7 | What should be areas of research priorities at NCORP sites? |

Abbreviations: COG, Children’s Oncology Group; CRA clinical research associate; NCORP, National Cancer Institute Community Oncology Research Program; PI, principal investigator.
Children’s Oncology Group NCORP Clinical Trial Enrollment

TABLE 2. Clinical Trial Enrollment: Barriers and Facilitators

| Research Domain | No. of Comments |
|-----------------|-----------------|
| **CCDR (16 responders, 16 comments)** | |
| **Barriers** | |
| Poor understanding and not engaged | 8 |
| Understand but cannot engage | 4 |
| Understand and not engaged | 1 |
| **Facilitator** | |
| Understand and engaged | 3 |
| **CCL (21 responders, 32 comments)** | |
| **Barriers** | |
| Inadequate institutional resources | 6 |
| Competing institutional standards | 5 |
| Inability to prioritize | 5 |
| Enrollment timing | 4 |
| Patient lost to follow-up | 3 |
| Lack of trials | 2 |
| Interest in the study | 2 |
| Consent fatigue | 2 |
| Labor intensive | 1 |
| Study duration | 1 |
| Reimbursement | 1 |
| **AYA (21 responders, 13 comments)** | |
| **Barrier** | |
| Institutional age limits | 3 |
| **Facilitator** | |
| AYA-focused coordinator | 5 |
| Partnership with adult oncology program | 3 |
| Streamlined processes | 1 |
| Access point into system | 1 |
| **MUS (22 responders, 28 comments)** | |
| **Barriers** | |
| Non-English, non-Spanish resources | 7 |
| Family travel | 1 |
| Inadequate translator support | 3 |
| **Facilitators** | |
| No issues | 11 |
| Shared culture of translator | 1 |
| In-person translators | 5 |
| **General barriers (18 responders, 32 comments)** | |
| **Barriers** | |
| Physician time | 9 |
| Adequate CRA support | 9 |
| Other research office support | 3 |
| Competing studies | 3 |

(continued on following page)

pre-identified specific research domains included the benefit of AYA program coordinators, the advantage of culturally matched in-person translators, an inability to prioritize cancer control studies, and the lack of understanding of cancer care delivery research (Table 2).

**DISCUSSION**

Given the positive association between clinical trial enrollment and survival, efforts to eliminate organizational, patient, and physician barriers are essential to maximizing outcomes for patients. In 2015, Freyer and Seibel21 introduced a conceptual model entitled Clinical Trial Pathway to Enrollment to highlight the steps required for clinical trial enrollment.21 Within every step of the process (a trial must first exist and then become available, presented, and accepted), oncologists serve an important facilitative role. Therefore, understanding physician attitude, attributes, and barriers are critical to improving clinical trial enrollment. Providers for adult patients with cancer have reported clinical trial awareness, rigid protocol design, insufficient staffing, beneficence toward patient care, and issues with time prioritization as barriers to clinical trial enrollment.7,8,13,21 Our findings suggest that NCORP pediatric oncologists experience similar limitations that fall into the areas of education, time, and resource allocation as the most prominent issues.

In response, the CNC is creating a series of Accrual Enhancement Activities to help pediatric NCORP investigators and their institutions to become vibrant components and contributors to the NCORP’s operation and mission, that is, strong accrual of minority/underserved patients and strong contributors to symptom management and cancer care delivery research. The framework includes a tripartite approach of enhancing education, engagement with leadership, and infrastructure support. First, suboptimal PI education is being addressed through more systematic exportation of transferable success strategies. Peer-to-peer mentoring, webinars, and embedded sessions at national meetings are in varying stages of development to address these deficiencies in knowledge. Second, COG PI incorporation into their respective NCORP leadership structure has been valued by those who practice in such a setting and will be nurtured by the CNC. Recently conducted cancer care delivery research launch calls between the NCI and NCORP PIs and administrators revealed that NCORP administrations were often unaware of COG activities (B. H. Pollock, personal communication, July 2019). To that effect, the CNC is currently developing a newsletter that will be distributed to COG PIs, lead CRAs, and their respective NCORP administrators and PIs. It is believed that through integrative dialogue between NCORP site leadership and administration that embedded COG PIs can better manage, prioritize, and advocate for their program needs. Third, the CNC strongly supports NCI initiatives to
address the most frequently self-reported barrier to physician engagement—time—by providing funding for NCORP site leadership involvement in supporting the clinical research enterprise.

Our findings suggest that additional support is needed to enhance physician engagement and activity in clinical trial enrollment. The challenges of providing institutional and professional investments are ongoing and contextual to the complex environmental, financial, and professional realities of limited resources and increasing health care provider responsibilities. Limitations inherent to this project’s design include potential sampling bias given survey response rates of 58% and 61%; nonresponders may have different experiences and opinions. In addition, our findings were limited to NCORP COG providers who as a group represent approximately 20% of all COG sites and do not include medical oncologists. Finally, because these surveys were developed to improve program quality, they lack vigorous validation and are specific to the survey sample, so the findings may have limited generalizability, particularly beyond the domain of NCORP COG members.

Despite these limitations, we believe that identifying education, time, and resources as barriers to clinical research engagement is credible because these findings closely match medical oncology reports and are consistent with ongoing phenomena such as CRA turnover, site case reimbursements, and the challenges of clinical research effort valuation (D. S. Dickens, personal communication, September 2019). We hope that it is the response to our findings, a provision of accrual enhancement activities, that will not only maximize the benefits experienced by patients at COG NCORP sites but also pertain to adult and pediatric, community, and academic oncologists alike.

**REFERENCES**

1. Bleyer A, Montello M, Budd T, et al: National survival trends of young adults with sarcoma: Lack of progress is associated with lack of clinical trial participation. Cancer 103:1891-1897, 2005

2. Chow CJ, Habermann EB, Abraham A, et al: Does enrollment in cancer trials improve survival? J Am Coll Surg 216:774-780, 2013; discussion 780-781

3. Wolfson JA, Sun CL, Wyatt LP, et al: Impact of care at comprehensive cancer centers on outcome: Results from a population-based study. Cancer 121:3885-3893, 2015

4. Wolfson J, Sun CL, Wyatt L, et al: Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma. Leukemia 31:1450-1453, 2017

5. Wolfson J, Sun CL, Wyatt L, et al: Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia: Impact of care at specialized cancer centers on survival outcome. Cancer Epidemiol Biomarkers Prev 26:312-320, 2017

6. Wolfson JA, Richman JS, Sun CL, et al: Causes of inferior outcome in adolescents and young adults with acute lymphoblastic leukemia: Across oncology services and regardless of clinical trial enrollment. Cancer Epidemiol Biomarkers Prev 27:1133-1141, 2018

7. Meropol NJ, Buzaglo JS, Millard J, et al: Barriers to clinical trial participation as perceived by oncologists and patients. J Natl Compr Canc Netw 5:655-664, 2007

8. Somkin CP, Ackerson L, Husson G, et al: Effect of medical oncologists’ attitudes on accrual to clinical trials in a community setting. J Oncol Pract 9:e275-e283, 2013

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT**

Disclosures provided by the authors and data availability statement (if applicable) are available with this article at DOI https://doi.org/10.1200/JOP.19.00707.

**AUTHOR CONTRIBUTIONS**

Conception and design: All authors

Provision of study material or patients: David S. Dickens

Collection and assembly of data: All authors

Data analysis and interpretation: All authors

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors
9. Unger JM, Cook E, Tai E, et al: The role of clinical trial participation in cancer research: Barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book 36:185-198, 2016
10. Green LA, Fryer GE Jr, Yawn BP, et al: The ecology of medical care revisited. N Engl J Med 344:2021-2025, 2001
11. McCaskill-Stevens W, Lys AP, Good M, et al: The NCI Community Oncology Research Program: What every clinician needs to know. Am Soc Clin Oncol Educ Book 33:e84, 2013
12. Minasian LM, Carpenter WR, Weiner BJ, et al: Translating research into evidence-based practice: The National Cancer Institute Community Clinical Oncology Program. Cancer 116:4440-4449, 2010
13. Jacobs SR, Weiner BJ, Reeve BB, et al: Organizational and physician factors associated with patient enrollment in cancer clinical trials. Clin Trials 11:565-575, 2014
14. Dimond EP, St Germain D, Nacpil LM, et al: Creating a “culture of research” in a community hospital: Strategies and tools from the National Cancer Institute Community Cancer Centers Program. Clin Trials 12:246-256, 2015
15. Bleyer A, Tai E, Siegel S: Role of clinical trials in survival progress of American adolescents and young adults with cancer and lack thereof. Pediatr Blood Cancer 65:e27074, 2018
16. Wolfson J, Sun CL, Kang T, et al: Impact of treatment site in adolescents and young adults with central nervous system tumors. J Natl Cancer Inst 106:dju166, 2014
17. Thomas SM, Malvar J, Tran H, et al: A prospective, observational cohort study comparing cancer clinical trial availability and enrollment between early adolescents/young adults and children. Cancer 124:983-990, 2018
18. Thomas SM, Malvar J, Tran HH, et al: A prospective comparison of cancer clinical trial availability and enrollment among adolescents/young adults treated at an adult cancer hospital or affiliated children's hospital. Cancer 124:4064-4071, 2018
19. Roth ME, O’Mara AM, Seibel NL, et al: Low enrollment of adolescents and young adults onto cancer trials: Insights from the Community Clinical Oncology Program. J Oncol Pract 12:e388-e395, 2016
19a. Roth ME, Unger JM, O’Mara AM, et al: Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era. Cancer Med 9:2146-2152, 2020
20. Freyer DR, Seibel NL: The clinical trials gap for adolescents and young adults with cancer: Recent progress and conceptual framework for continued research. Curr Pediatr Rep 3:137-145, 2015
21. Benson AB III, Pregler JP, Bean JA, et al: Oncologists’ reluctance to accrue patients onto clinical trials: An Illinois cancer center study. J Clin Oncol 9:2067-2075, 1991
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Understanding the Barriers to Pediatric Oncologist Engagement and Accrual to Clinical Trials in National Cancer Institute–Designated Community Oncology Research Programs

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Michael E. Roth
Research Funding: Eisai

Brad H. Pollock
Consulting or Advisory Role: Astellas Pharma, LEO Pharma

Anne-Marie Langevin
Research Funding: Roche (Inst), Genentech (Inst), Bristol-Myers Squibb (Inst), Incyte (Inst)

No other potential conflicts of interest were reported.